Alan Colowick

Partner at Sofinnova Ventures, Inc.

Alan Colowick

Alan Colowick

Partner at Sofinnova Ventures, Inc.

Overview
Career Highlights

Gloucester Pharmaceuticals, Inc.

RelSci Relationships

2612

Number of Boards

12

Birthday

1962

Age

57

Contact Data
Trying to get in touch with Alan Colowick? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Alan Colowick likely has professional access to. A relationship does not necessarily indicate a personal connection.

Executive Partner, Private Equity at Sofinnova Ventures, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Windmil Therapeutics, Inc.

Relationship likelihood: Strong

Former Chief Financial Officer & Chief Accounting Officer at Sienna Biopharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder & Vice Chairman at Celularity, Inc.

Relationship likelihood: Strong

Partner at Rho Ventures

Relationship likelihood: Strong

Founder at Principia Biopharma, Inc.

Relationship likelihood: Strong

President, Chief Executive Officer & Director at Principia Biopharma, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Castlight Health, Inc.

Relationship likelihood: Strong

Founder at Samsara Biocapital LLC

Relationship likelihood: Strong

Founder & Chairman at Celgene Corp.

Relationship likelihood: Strong

Paths to Alan Colowick
Potential Connections via
Relationship Science
You
Alan Colowick
Partner at Sofinnova Ventures, Inc.
Education
MD

A leader in the Biomedical Revolution, Stanford Medicine has a long tradition of leadership in pioneering research, creative teaching protocols and effective clinical therapies. Our close proximity to the resources of the university—including the Schools of Business, Law, Humanities and Sciences and Engineering—our seamless relationship with our affiliated adult and children’s hospitals and our ongoing associations with the entrepreneurial endeavors of Silicon Valley make us uniquely positioned to accelerate the pace at which new knowledge is turned into tangible health benefits.

MPH

The oldest corporation in the Western Hemisphere is the Harvard Corporation, known formally as the President and Fellows of Harvard College. It is the smaller of Harvard’s two governing boards; the other is the Board of Overseers. Following are the members of the Harvard Corporation.

B.S. in Molecular Biology

The University of Colorado advances the economy, health and culture of Colorado and beyond, educating more than 435,000 students who have become catalysts in business, arts, health and community growth. CU’s four campuses feature top-tier faculty and hands-on learning opportunities in an environment where students thrive.

Career History
Chief Executive Officer
2008 - Prior

Gloucester Pharmaceuticals, Inc. develops products for the treatment of cancer patients. Its programs include cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), and multiple myeloma. The company was founded in May 2003 and is headquartered in Cambridge, MA

Senior Director of Medical Affairs
Prior

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Chief Medical Officer
2005 - 2006

Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA

Boards & Committees
Independent Director
2019 - Current

Personalis, Inc. provides genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.

Director
2018 - Current

Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA.

Chairman
2017 - Current

Principia Biopharma, Inc. is a biopharmaceutical company, which engages in design and development oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to purpose-design and develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline include PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 28, 2008 and is headquartered in South San Francisco, CA.

Political Donations
$250
2012

Former President of United States

$500
2011

Former President of United States

$2,300
2008

Former President of United States

Transactions
Details Hidden

Nora Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

Gloucester Pharmaceuticals, Inc. raised money in a private placement transaction

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Alan Colowick. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Alan Colowick's profile does not indicate a business or promotional relationship of any kind between RelSci and Alan Colowick.